375 related articles for article (PubMed ID: 19799125)
1. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
[TBL] [Abstract][Full Text] [Related]
2. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
4. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
[TBL] [Abstract][Full Text] [Related]
8. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
9. Front-line management of diffuse large B cell lymphoma.
Cabanillas F
Curr Opin Oncol; 2010 Nov; 22(6):642-5. PubMed ID: 20811278
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Fabbri A; Gozzetti A; Rigacci L
Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
[No Abstract] [Full Text] [Related]
11. [Clinical analysis of primary gastric diffuse large B-cell lymphoma].
Zhang J; Wang MY; Xu LC; Gu SY; Cao JN; Hu XC; Hong XN
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):614-8. PubMed ID: 21122416
[TBL] [Abstract][Full Text] [Related]
12. Relevance of the International Prognostic Index in the rituximab era.
Tay K; Tai D; Tao M; Quek R; Ha TC; Lim ST
J Clin Oncol; 2011 Jan; 29(1):e14; author reply e15. PubMed ID: 21115864
[No Abstract] [Full Text] [Related]
13. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
Scandurra M; Mian M; Greiner TC; Rancoita PM; De Campos CP; Chan WC; Vose JM; Chigrinova E; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Montes-Moreno S; Piris MA; Facchetti F; Tucci A; Nomdedeu JF; Lazure T; Lambotte O; Uccella S; Pinotti G; Pruneri G; Martinelli G; Young KH; Tibiletti MG; Rinaldi A; Zucca E; Kwee I; Bertoni F
Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
15. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma.
Park Y; Choi YJ; Park SJ; Lee SR; Sung HJ; Park KH; Kim SJ; Choi CW; Jung KY; Kim BS
Acta Haematol; 2011; 126(2):79-86. PubMed ID: 21540579
[TBL] [Abstract][Full Text] [Related]
17. Primary colonic lymphoma: an analysis of 74 cases with localized large-cell lymphoma.
Tang TC; Kuo MC; Chang H; Dunn P; Wang PN; Wu JH; Lin TL; Hung YS; Kuo TT; Shih LY
Eur J Haematol; 2011 Jul; 87(1):28-36. PubMed ID: 21535155
[TBL] [Abstract][Full Text] [Related]
18. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F
Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
